With notable achievements, tumor immunotherapy focused on the chemokine system has recently been introduced (12, 13).Although chemokine and chemokine-receptor-based therapies for CRC have yet to be integrated into clinical practice, the CXCR4 inhibitor LY2510924 has exhibited a favorable clinical safety profile and tolerability, demonstrating a 20% overall response rate in phase I clinical trials (4). Here, CXCR4 is linked to colorectal carcinoma.